logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

SpyGlass Pharma has raised $75 million in a Series D funding round led by Sands Capital to further its Drug Delivery Platform for glaucoma patients.

Jun 02, 2025•7 months ago

Amount Raised

$75 Million

Round Type

series d

Aliso ViejoHealth Care

Investors

Vertex Ventures HcSamsara Bio CapitalVensana CapitalRa CapitalNew Enterprise Associates (Nea)Gilde HealthcareSands Capital

Description

SpyGlass Pharma, an ophthalmic biotechnology company, confirmed a $75 million Series D financing round. This funding will aid in advancing their Drug Delivery Platform through two Phase III pivotal trials. The round was joined by Gilde Healthcare and existing investors. CEO Patrick Mooney expressed gratitude for investor support, highlighting the commitment to addressing unmet needs in ophthalmic patient care.

Company Information

Company

SpyGlassPharma

Location

27061 Aliso Creek Road

Aliso Viejo, California, United States

About

SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech